New Delhi, India – From April 14 to April 16, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the annual meeting of National Interventional Council ("NIC") held in New Delhi, India to display its innovative product Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). During the meeting, six live cases were performed by six top national key opinion leaders ("KOLs") who used Firehawk® to treat complex lesions like bifurcation, SVGs and etc., and achieved successful results.
NIC is the Interventional faction of the Cardiological Society of India ("CSI"), a recognized body of all cardiologists in India. Every year in the month of April, CSI-NIC organizes a three-day knowledge exchange platform.
In the live cases, all operators highlighted the key features of Firehawk® such as lower polymer and lower drug load compared to the second generation and the third generation stents. They unanimously appreciated the innovative TES technology of Firehawk® and its acute performance. In Particular, its side branch access was highlighted by one of the top KOLs from India during the live case. Also during the NIC annual meeting, one of the top KOLs from India shared the clinical data of Firehawk®.
Recently, Indian government authority unveiled new price cap for cardiac interventional DES, which will exert great influence on India's interventional market and may even lead to industry reshuffle. "In the face of the new policy, it is quite challenging for Firehawk®'s market expansion in India in its very early stage. But as a country that has the third largest amount of PCI cases in the world, India is a market we will definitely pay special efforts to," said Dr. Linda Lin, First Vice President of MicroPort® International Business. "We will keep cultivating the India market to provide ideal solutions for local patients with coronary diseases."